A Multicenter, Single-Arm Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma.

Trial Profile

A Multicenter, Single-Arm Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2014

At a glance

  • Drugs Lenalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Registrational
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 21 Nov 2009 Planned number of patients changed from 2000 to 12,000 as reported by M.D. Anderson Cancer Center record.
    • 15 Sep 2009 Actual number of patients (1913) added as reported by ClinicalTrials.gov.
    • 15 Sep 2009 Actual number of patients (1913) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top